Idiopathic Thrombocytopenic Purpura

ITP study finds Gamunex safe and efficacious for patients

Published in Cancer Weekly, June 29th, 2004

Bayer HealthCare, LLC, biological products division (Bayer BP), announced that recently published data surrounding its GIV, Gamunex, Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified, met both primary and secondary endpoints for safety and efficacy in an evaluation of the drug's use in the treatment of ITP (Idiopathic [immune] Thrombocytopenic Purpura).

Gamunex was approved for the treatment of ITP and other indications in the United States and Canada in August 2003, as well as in Germany earlier in 2004.

The primary endpoint was to achieve similar platelet count elevation after treatment with Gamunex compared with standard...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry